Omega-3 polyunsaturated fatty acids (Omacor) for hypertriglyceridemia.
D018849:Controlled Clinical Trials as Topic; D003327:Coronary Disease / Q000453:epidemiology; D003365:Costs and Cost Analysis; D004042:Dietary Fats, Unsaturated / Q000627:therapeutic use; D004281:Docosahexaenoic Acids / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D004347:Drug Interactions; D004415:Dyspepsia / Q000139:chemically induced; D015118:Eicosapentaenoic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D015525:Fatty Acids, Omega-3 / Q000191:economics / Q000627:therapeutic use*; D005231:Fatty Acids, Unsaturated / Q000191:economics / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology; D015228:Hypertriglyceridemia / Q000178:diet therapy / Q000188:drug therapy*
D004042:Dietary Fats, Unsaturated; D004338:Drug Combinations; D015525:Fatty Acids, Omega-3; D005231:Fatty Acids, Unsaturated; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D004281:Docosahexaenoic Acids; D015118:Eicosapentaenoic Acid; C405603:Omacor